News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
FREMONT, Calif. , Oct. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology
View HTML
Toggle Summary Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
FREMONT, Calif. , Oct. 4, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018 , from 8 to 10 a.m. ET in New York City . This year's event is the first of an anticipated annual series of events, and will
View HTML
Toggle Summary Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
FREMONT, Calif. , Sept. 13, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) requesting U.S. marketing authorization of tenapanor for the treatment of patients with irritable bowel
View HTML
Toggle Summary Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
FREMONT, Calif. , Aug. 29, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal Science Translational Medicine .
View HTML
Toggle Summary Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
Operating Runway Extended to Mid-2020 Preparing to Submit NDA for Tenapanor in IBS-C in Early Q4 2018 Conference Call to be Held Today at 4:30 p.m. ET FREMONT, Calif. , Aug. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the second
View HTML
Toggle Summary Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
FREMONT, Calif. , Aug. 1, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018 . Management will host a conference call and webcast that afternoon at 4:30 p.m.
View HTML
Toggle Summary Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
FREMONT, Calif. , May 29, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present a company overview at the Jefferies Global Healthcare Conference on Tuesday, June 5, 2018 at 2:30 p.m. ET in New York City .
View HTML
Toggle Summary Ardelyx Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , May 22, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before underwriting discounts and commissions, for gross proceeds of
View HTML
Toggle Summary Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the Life Sciences Group at Bridge Bank , a division of Western Alliance Bank .
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock. All of the shares to be sold in the offering will be offered by Ardelyx .
View HTML